vs
ACADIA PHARMACEUTICALS INC（ACAD）与Enact Holdings, Inc.（ACT）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是ACADIA PHARMACEUTICALS INC的1.1倍（$312.7M vs $284.0M），ACADIA PHARMACEUTICALS INC同比增速更快（9.4% vs 3.6%），过去两年ACADIA PHARMACEUTICALS INC的营收复合增速更高（17.5% vs 3.6%）
阿卡迪亚制药是一家总部位于美国加利福尼亚州圣地亚哥德尔马地区的生物制药企业，专注于中枢神经系统相关疾病治疗药物的研发、生产与商业化，致力于为全球患者提供创新的临床治疗方案。
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
ACAD vs ACT — 直观对比
营收规模更大
ACT
是对方的1.1倍
$284.0M
营收增速更快
ACAD
高出5.8%
3.6%
两年增速更快
ACAD
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $284.0M | $312.7M |
| 净利润 | $273.6M | — |
| 毛利率 | 90.8% | — |
| 营业利润率 | 6.1% | 71.3% |
| 净利率 | 96.3% | — |
| 营收同比 | 9.4% | 3.6% |
| 净利润同比 | 90.3% | — |
| 每股收益（稀释后） | $1.61 | $1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACADACT
| Q4 25 | $284.0M | $312.7M | ||
| Q3 25 | $278.6M | $311.5M | ||
| Q2 25 | $264.6M | $304.9M | ||
| Q1 25 | $244.3M | $306.8M | ||
| Q4 24 | $259.6M | $301.8M | ||
| Q3 24 | $250.4M | $309.6M | ||
| Q2 24 | $242.0M | $298.8M | ||
| Q1 24 | $205.8M | $291.6M |
净利润ACADACT
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $26.7M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $33.4M | — | ||
| Q1 24 | $16.6M | — |
毛利率ACADACT
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
营业利润率ACADACT
| Q4 25 | 6.1% | 71.3% | ||
| Q3 25 | 12.8% | 67.4% | ||
| Q2 25 | 12.2% | 70.4% | ||
| Q1 25 | 7.9% | 68.9% | ||
| Q4 24 | 59.1% | 68.9% | ||
| Q3 24 | 12.6% | 74.1% | ||
| Q2 24 | 12.6% | 78.6% | ||
| Q1 24 | 7.4% | 70.6% |
净利率ACADACT
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | — | ||
| Q2 25 | 10.1% | — | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 8.0% | — |
每股收益（稀释后）ACADACT
| Q4 25 | $1.61 | $1.23 | ||
| Q3 25 | $0.42 | $1.10 | ||
| Q2 25 | $0.16 | $1.11 | ||
| Q1 25 | $0.11 | $1.08 | ||
| Q4 24 | $0.86 | $1.05 | ||
| Q3 24 | $0.20 | $1.15 | ||
| Q2 24 | $0.20 | $1.16 | ||
| Q1 24 | $0.10 | $1.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.7M | $582.5M |
| 总债务越低越好 | — | $744.5M |
| 股东权益账面价值 | $1.2B | $5.4B |
| 总资产 | $1.6B | $6.9B |
| 负债/权益比越低杠杆越低 | — | 0.14× |
8季度趋势，按日历期对齐
现金及短期投资ACADACT
| Q4 25 | $177.7M | $582.5M | ||
| Q3 25 | $258.0M | $545.6M | ||
| Q2 25 | $253.6M | $616.0M | ||
| Q1 25 | $217.7M | $639.0M | ||
| Q4 24 | $319.6M | $602.8M | ||
| Q3 24 | $155.1M | $674.9M | ||
| Q2 24 | $177.1M | $711.3M | ||
| Q1 24 | $204.7M | $624.3M |
总债务ACADACT
| Q4 25 | — | $744.5M | ||
| Q3 25 | — | $744.1M | ||
| Q2 25 | — | $743.8M | ||
| Q1 25 | — | $743.4M | ||
| Q4 24 | — | $743.0M | ||
| Q3 24 | — | $742.7M | ||
| Q2 24 | — | $742.4M | ||
| Q1 24 | — | $746.1M |
股东权益ACADACT
| Q4 25 | $1.2B | $5.4B | ||
| Q3 25 | $917.3M | $5.3B | ||
| Q2 25 | $822.4M | $5.2B | ||
| Q1 25 | $765.2M | $5.1B | ||
| Q4 24 | $732.8M | $5.0B | ||
| Q3 24 | $577.2M | $5.0B | ||
| Q2 24 | $516.7M | $4.8B | ||
| Q1 24 | $464.0M | $4.7B |
总资产ACADACT
| Q4 25 | $1.6B | $6.9B | ||
| Q3 25 | $1.3B | $6.9B | ||
| Q2 25 | $1.2B | $6.8B | ||
| Q1 25 | $1.1B | $6.7B | ||
| Q4 24 | $1.2B | $6.5B | ||
| Q3 24 | $976.9M | $6.6B | ||
| Q2 24 | $914.1M | $6.3B | ||
| Q1 24 | $855.1M | $6.3B |
负债/权益比ACADACT
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 0.14× | ||
| Q2 25 | — | 0.14× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-48.7M | $724.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -0.18× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACADACT
| Q4 25 | $-48.7M | $724.5M | ||
| Q3 25 | $74.3M | $192.0M | ||
| Q2 25 | $64.0M | $119.5M | ||
| Q1 25 | $20.3M | $226.7M | ||
| Q4 24 | $40.4M | $686.3M | ||
| Q3 24 | $63.2M | $188.1M | ||
| Q2 24 | $25.0M | $144.7M | ||
| Q1 24 | $29.1M | $187.3M |
自由现金流ACADACT
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ACADACT
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ACADACT
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ACADACT
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ACT
暂无分部数据
